Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to $3.6 million.

  • Viemed Healthcare's Change in Accured Expenses rose 706.13% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3882.32%. This contributed to the annual value of $2.9 million for FY2024, which is 4238.76% down from last year.
  • Latest data reveals that Viemed Healthcare reported Change in Accured Expenses of $3.6 million as of Q3 2025, which was up 706.13% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Viemed Healthcare's Change in Accured Expenses peaked at $3.6 million during Q3 2025, and registered a low of -$3.7 million during Q2 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was $89000.0 (2021), whereas its average is $417210.5.
  • In the last 5 years, Viemed Healthcare's Change in Accured Expenses surged by 355955.06% in 2022 and then tumbled by 29674.97% in 2024.
  • Quarter analysis of 5 years shows Viemed Healthcare's Change in Accured Expenses stood at -$311000.0 in 2021, then plummeted by 99.68% to -$621000.0 in 2022, then soared by 240.58% to $873000.0 in 2023, then plummeted by 50.4% to $433000.0 in 2024, then skyrocketed by 722.86% to $3.6 million in 2025.
  • Its Change in Accured Expenses stands at $3.6 million for Q3 2025, versus $1.1 million for Q2 2025 and -$3.0 million for Q1 2025.